JP2023520989A - １型糖尿病の予防および治療に有用なｔレジトープ構築物 - Google Patents

１型糖尿病の予防および治療に有用なｔレジトープ構築物 Download PDF

Info

Publication number
JP2023520989A
JP2023520989A JP2022558189A JP2022558189A JP2023520989A JP 2023520989 A JP2023520989 A JP 2023520989A JP 2022558189 A JP2022558189 A JP 2022558189A JP 2022558189 A JP2022558189 A JP 2022558189A JP 2023520989 A JP2023520989 A JP 2023520989A
Authority
JP
Japan
Prior art keywords
blood component
cells
resitope
regulatory
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558189A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021195508A5 (enExample
Inventor
デ・グルート・アンネ
マーティン・ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epivax Inc
Original Assignee
Epivax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epivax Inc filed Critical Epivax Inc
Publication of JP2023520989A publication Critical patent/JP2023520989A/ja
Publication of JPWO2021195508A5 publication Critical patent/JPWO2021195508A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022558189A 2020-03-27 2021-03-26 １型糖尿病の予防および治療に有用なｔレジトープ構築物 Pending JP2023520989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000590P 2020-03-27 2020-03-27
US63/000,590 2020-03-27
PCT/US2021/024377 WO2021195508A1 (en) 2020-03-27 2021-03-26 Tregitope constructs useful in the prevention and treatment of type 1 diabetes

Publications (2)

Publication Number Publication Date
JP2023520989A true JP2023520989A (ja) 2023-05-23
JPWO2021195508A5 JPWO2021195508A5 (enExample) 2024-02-14

Family

ID=77890539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558189A Pending JP2023520989A (ja) 2020-03-27 2021-03-26 １型糖尿病の予防および治療に有用なｔレジトープ構築物

Country Status (4)

Country Link
US (1) US20230158165A1 (enExample)
EP (1) EP4126907A1 (enExample)
JP (1) JP2023520989A (enExample)
WO (1) WO2021195508A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1191273C (zh) * 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US20170173128A1 (en) * 2013-12-06 2017-06-22 Moderna TX, Inc. Targeted adaptive vaccines
EP3691673A4 (en) * 2017-10-05 2021-06-09 Epivax, Inc. REGULATORY T-LYMPHOCYTE EPITOPES

Also Published As

Publication number Publication date
US20230158165A1 (en) 2023-05-25
EP4126907A1 (en) 2023-02-08
WO2021195508A1 (en) 2021-09-30

Similar Documents

Publication Publication Date Title
JP2023515386A (ja) 制御性ｔ細胞エピトープと脱寛容化ｓａｒｓ－ｃｏｖ－２抗原
CN107011431B (zh) 调节性t细胞表位、组合物及其用途
JP2023106434A (ja) 制御性ｔ細胞エピトープ
JP2023520989A (ja) １型糖尿病の予防および治療に有用なｔレジトープ構築物
US11911414B2 (en) Regulatory T cell epitopes
US20230279072A1 (en) Regulatory t cell epitopes
US20240173377A1 (en) Retro - inverso regulatory t cell epitopes
JP2023538002A (ja) 制御性ｔ細胞エピトープ
JPWO2021195508A5 (enExample)
JPWO2022036193A5 (enExample)
JPWO2021195492A5 (enExample)
HK40045381A (en) Regulatory t cell epitopes, compositions and uses thereof
HK1242342A1 (en) Regulatory t cell epitopes, compositions and uses thereof
HK1197250B (en) Regulatory t cell epitopes, compositions and uses thereof

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20240205

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240205

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240213